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Abstract
Introduction: Identification of useful markers associated with poor prognosis in breast cancer patients is critically
needed. We previously showed that expression of vascular endothelial growth factor receptor-1 mRNA in
peripheral blood may be useful to predict distant metastasis in gastric cancer patients. However, expression of
vascular endothelial growth factor receptor-1 mRNA in peripheral blood of breast cancer patients has not yet been
studied.
Methods: Real-time reverse transcriptase-PCR was used to analyze vascular endothelial growth factor receptor-1
mRNA expression status with respect to various clinical parameters in 515 patients with breast cancer and 25
controls.
Results: Expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood was higher in
breast cancer patients than in controls. Increased vascular endothelial growth factor receptor-1 mRNA expression
was associated with large tumor size, lymph node metastasis and clinical stage. Patients with high vascular
endothelial growth factor receptor-1 mRNA expression also experienced a poorer survival rate than those with low
expression levels, including those patients with triple-negative type and luminal-HER2(-) type disease.
Conclusions: Expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood may be useful
for prediction of poor prognosis in breast cancer, especially in patients with triple-negative type and luminal-HER2
(-) type disease.
Introduction
Breast cancer is the most common malignancy among
woman and is one of the major causes of death. During
the last several decades, many studies have been con-
ducted to identify markers that indicate breast cancer
recurrence and/or prognosis, including disseminated
tumor cells (DTCs) and circulating tumor cells (CTCs)
[1,2]. However, no precise markers for prediction of
relapse-free survival (RFS) and/or overall survival (OS)
in patients with breast cancer have yet been identified.
Quantitative techniques, such as reverse transcriptase
(RT)-PCR, are not currently performed to identify
recurrence and survival factors for breast cancer in a
daily procedure. Although the high sensitivity of RT-
PCR can result in false positives, its power of detection
is more sensitive than that of immunohistochemistry.
Recently, Kaplan et al. reported that bone marrow
derived cells (BMDCs) expressing vascular endothelial
growth factor receptor-1 (VEGFR-1) play an important
role in the development of malignant metastasis [3]. These
investigators showed that BMDCs form a “metastatic
niche” in the lungs prior to the arrival of cancer cells, and
that blockade of VEGFR-1 prevented this BMDC infiltra-
tion and metastatic niche formation. Their findings sug-
gest that VEGFR-1-expressing cells in the bone marrow or
peripheral blood may contribute to cancer metastasis and
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Our previous study demonstrated that VEGFR-1
mRNA expression in the peripheral blood of gastric can-
cer patients is associated with pathological stage and
recurrence. However, no reports have yet evaluated the
clinicopathologic significance or prognostic value of per-
ipheral blood VEGFR-1 mRNA expression in breast can-
cer patients. Therefore, the aim of the current study was
to evaluate the expression of VEGFR-1 mRNA in the per-
ipheral blood of >500 breast cancer patients and to define
its clinicopathologic and prognostic significance with
respect to recurrence and survival.
Materials and methods
Patients
This study enrolled 515 breast cancer patients with stage
0 to III disease who underwent surgery in the National
Kyushu Cancer Center Hospital, Japan between 2000 and
2004. In addition, 25 patients with no history of cancer
who underwent abdominal surgery between 2001 and
2004 were recruited as negative controls; this group
included 16 cases of gallstones, 3 cases of common bile
duct stones and 6 cases of incisional hernia that occurred
following curative surgery more than five years pre-
viously. The mean postoperative period was 44.4 months
(range, 4 to 86 months). Clinical stages and pathological
features of primary tumors were defined according to the
classification of the International Union Against Cancer
[4]. Patient ages ranged from 28 to 85 years. All of the
women included provided written informed consent for
participation in the study, and the ethics committees of
the Kyushu University and National Kyushu Cancer
Center Hospital, Japan, approved the research project.
Blood sampling
Aspiration of peripheral blood was conducted under gen-
eral anesthesia immediately prior to surgery. Peripheral
blood was obtained through a venous catheter. The first 1
mL of peripheral blood was discarded to avoid contamina-
tion by epidermal cells. A 1 mL sample of peripheral
whole blood from each patient was immediately mixed
vigorously with 4 mL ISOGEN-LS (NIPPON GENE,
Toyama, Japan) and stored at -80°C until RNA extraction.
Total RNA extraction and first-strand cDNA synthesis
Total RNA was extracted according to the ISOGEN-LS
manufacturer’s protocols. All of the clinical samples
obtained from the National Kyushu Cancer Center Hospi-
tal were sent to our institute. RT reactions were performed
as described previously [5,6]. First-strand cDNA was
synthesized from 2.7 µg total RNA in a 30 µL reaction
mixture containing 5 µL 5X RT reaction buffer (Gibco
BRL, Gaithersburg, MD, USA), 200 µM dNTPs, 100 µM
solution random hexadeoxynucleotide primer mixture,
50 units RNasin (Promega, Madison, WI, USA), 2 µL
0.1 M dithiothreitol, and 100 units Moloney murine leuke-
mia virus RT (BRL). The mixture was incubated at 37°C
for 60 minutes, heated to 95°C for 10 minutes, and subse-
quently chilled on ice.
Quantitative RT-PCR
The following VEGFR-1 mRNA primers were used:
sense primer, 5’-TCATGAATGTTTCCCTGCAA-3’;
antisense primer, 5’-GGAGGTATGGTGCTTCCTGA-3’.
Ribosomal protein S27a (RPS27A) was used as an inter-
nal control. The following RPS27A primers were used:
sense primer, 5’-TCGTGGTGGTGCTAAGAAAA-3’;
antisense primer, 5’-TCTCGACGAAGGCGACTAAT-3’.
Real-time monitoring of PCR reactions was performed
using the LightCycler™ system (Roche Applied Science,
Indianapolis, IN, USA) and SYBR green I dye (Roche
Diagnostics). Monitoring was performed according to
the manufacturer’s instructions, as described previously
[7,8]. In brief, a master mixture was prepared on ice,
containing 500 ng cDNA of each gene, 2 µL LC DNA
Master SYBR green I mix, 50 ng primers and 2.4 µL
25 mM MgCl2. The final volume was then adjusted to
20 µL with water. After the reaction mixture was loaded
into the glass capillary tube, PCR was conducted under
the following cycling conditions: initial denaturation at
95°C for 10 minutes, followed by 40 cycles of denatura-
tion at 95°C for 8 sec, annealing at 68°C for 8 sec and
extension at 72°C for 2 sec. After amplification, the pro-
ducts were subjected to a temperature gradient from
72°C to 95°C at 0.1°C/sec, under continuous fluores-
cence monitoring to produce a melting curve of the
products.
Data analysis
Expression levels of VEGFR-1 and RPS27A mRNAs were
determined by comparison with the cDNA from Human
Universal Reference Total RNA (Clontech, Palo Alto,
CA, USA). After proportional baseline adjustment, the fit
point method was employed to determine the cycle in
which the log-linear signal was first distinguishable from
baseline, and then that cycle number was used as a cross-
ing-point value. The standard curve was produced by
measuring the crossing point of each standard value and
plotting it against the logarithmic value of the concentra-
tions. Concentrations were calculated by plotting their
crossing points against the standard curve, and were
adjusted by RPS27A content. Taking into consideration
the clinical application of the current study, the 95% con-
fidence interval (CI) was used as the upper limit of a nor-
mal case cutoff value (bone marrow, 0.12; peripheral
blood, 0.059). The 95% value of a normal case according
to the reference intervals of the Clinical and Laboratory
Standards Institute [9] was established, and the reference
limit was regarded as the cutoff value. Levels higher or
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lower than the cutoff value were considered “positive”
and “negative,” respectively. The sensitivity and specifi-
city of the data were determined to evaluate the legiti-
macy of the cutoff value.
Statistics
For continuous variables, the data were expressed as
mean ± standard deviation. The relationships between
VEGFR-1 mRNA expression and clinicopathological fac-
tors were analyzed using the chi-square test and Krus-
kal-Wallis test. The Kaplan-Meier method was used to
estimate the occurrence probability of an event, where
the events included death, relapse, local recurrence and
observation of distant metastasis. The generalized log-
rank test was applied to compare the occurrence prob-
ability. Cox proportional-hazards models were fitted for
multivariate analysis. All tests were analyzed using JMP
software (SAS Institute, Inc., Cary, NC, USA). Statistical




Blood samples from 25 normal control cases and 515
breast cancer patients were analyzed for VEGFR-1 and
RPS27A gene expression levels by quantitative real-time
RT-PCR; expression levels of VEGFR-1 mRNA were
corrected for those of RPS27A mRNA. An overview of
patient characteristics is provided in Table 1.
Expression of VEGFR-1 mRNA in peripheral blood of
surgical breast cancer patients
Figure 1 shows peripheral blood VEGFR-1 mRNA levels
of breast cancer patients and controls. The mean
expression level of VEGFR-1 mRNA in cancer patients
(0.25 ± 1.76) was significantly higher than that of the
control group (0.03 ± 0.05; P <0.05). Expression levels
of VEGFR-1 mRNA in stage III breast cancer patients
(1.18 ± 3.97) were significantly higher than those of
either stage I (0.12 ± 0.53; P <0.01) or stage II (0.12 ±
0.64; P <0.01) patients (Figure 2).
Association between VEGFR-1 mRNA expression level and
clinicopathological features
Correlations between VEGFR-1 mRNA levels and clinico-
pathological variables are summarized in Table 2. By the
predetermined cutoff value (0.059), 49 patients (9.52%)
were positive for VEGFR-1 mRNA expression. Signifi-
cantly higher expression was observed in the following
patient subgroups: large tumor size (P < 0.05), lymph node
metastasis (P < 0.05), clinical stage (P < 0.01), postopera-
tive recurrence (P <0.01) and poor prognosis (P <0.0001).
Association between VEGFR-1 mRNA expression level and
survival
At a median follow-up of 44.4 months, 76 RFS events
and 27 OS events had been registered. The five-year
Table 1 Clinicopathologic characteristics of the patients
Factors No. %
Patients enrolled 515 100.0
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RFS rate (69.0%) was significantly lower in VEGFR-1-
positive patients than in VEGFR-1-negative patients
(82.5%; P <0.05; Figure 3A). The five-year OS rate
(80.5%) was also significantly lower in VEGFR-1-positive
patients than in VEGFR-1-negative patients (94.4%; P <
0.01; Figure 3B).
Univariate and multivariate analyses were performed
to identify factors associated with survival (Table 3).
Univariate analysis identified lymph node metastasis,
hormone receptor status, elevated preoperative CEA
level (>5.1 ng/mL), tumor size, nuclear grade, lymphatic
involvement and VEGFR-1 mRNA expression levels as
adverse prognostic factors for OS (P <0.05 for each fac-
tor). Multivariate analysis also indicated that high
VEGFR-1 mRNA expression was an independent factor
for OS (relative risk (RR), 2.00; 95% CI, 1.19 to 3.25, P <
0.01), as well as lymph node metastasis (RR, 2.67; 95%
CI, 1.53 to 4.96, P <0.001) and hormone receptor status
(RR, 2.65; 95% CI, 1.62 to 4.43, P <0.001).
Association between VEGFR-1 mRNA expression level and
survival by subtype of breast cancer
In patients with hormone receptor-positive, HER2-nega-
tive, the five-year OS rate (57.1%) was significantly
Figure 1 VEGFR-1 mRNA expression in peripheral blood from breast cancer patients. Expression of VEGFR-1 mRNA is significantly elevated
in peripheral blood in 515 patients of breast cancer in comparison to that in 25 normal control patients.
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lower in VEGFR-1-positive patients (n = 12) compared
to that in VEGFR-1-negative patients (n = 246; 94.2%;
P < 0.01; Figure 4a).
In patients with triple-negative breast cancer (that is,
cancers that were estrogen receptor-negative, proges-
terone receptor-negative and HER2-negative), the five-
year OS rate (50%) was significantly lower in VEGFR-
1-positive patients (n = 6) compared to that in
VEGFR-1-negative patients (n = 55; 79.9%; P <0.05;
Figure 4b).
However, there was no significant difference between
VEGFR-1-positive and VEGFR-1-negative in patients
with HER2-positive regardless of the presence of the
hormone receptor (data not shown).
Figure 2 VEGFR-1 mRNA expression in clinical stage of breast cancer patients. The higher VEGFR-1 mRNA expression was observed in
patients with stage III in comparison with stage I and II patients (P <0.01, respectively).
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Discussion
We have investigated the correlation between VEGFR-1
mRNA expression in peripheral blood of a large number
of breast cancer patients and clinicopathologic factors,
RFS and OS. The present results reveal that VEGFR-1
mRNA expression levels are very high in breast cancer
patients and are associated with clinical stage, recurrence
and prognosis. In addition, VEGFR-1 mRNA expression
levels are associated with tumor size and lymph node
metastasis (Table 2). These results are consistent with our
previous reports, in which peripheral blood VEGFR-1
mRNA expression levels were significantly higher in gas-
tric cancer patients compared to non-cancer patients, and
VEGFR-1 mRNA expression levels were associated with
clinical stage [10,11].
In the present study, patients with VEGFR-1 mRNA
overexpression experienced a higher rate of recurrence
and a poorer prognosis compared to VEGFR-1-negative
patients. Moreover, Kaplan-Meier analysis indicated that
patients with VEGFR-1 mRNA overexpression had
Table 2 Correlation of clinicopathologic characterestics and VEGFR1 mRNA expression
VEGFR1 mRNA in peripheral blood
negative Positive
(n = 466) (n = 49)
Factors No. % No. % P
Age (mean ± SD) 55.5 ± 11.5 54.5 ± 11.5 0.66
Tumor size
small (Tis to T1) 189 40.6 13 26.5 <0.05
large (T2 to T4) 277 59.4 36 73.5
Lymphnode metastasis
negative 316 67.8 26 53.1 <0.05
positive 150 32.2 23 46.9
Lymphatic involvement
negative 289 62.0 27 55.1 0.34
positive 177 38.0 22 44.9
Vascular involvement
negative 438 94.0 43 87.8 0.09
positive 28 6.0 6 12.2
Nuclear grade
I/II 311 66.7 35 71.4 0.50
III 155 33.3 14 28.6
Hormone receptor
negative 112 24.0 11 22.4 0.80
positive 354 76.0 38 77.6
HER-2/NEU
negative 301 86.0 18 94.7 0.23
positive 49 14.0 1 5.3
CEA
<5.0 408 94.9 44 95.7 0.82
>5.1 22 5.1 2 4.3
Stage
0 6 1.3 0 0.0 <0.01
I 143 30.7 12 24.5
II 290 62.2 26 53.1
III 27 5.8 11 22.4
Recurrence
negative 404 86.7 34 69.4 <0.01
positive 62 13.3 15 30.6
Prognosis
alive 449 96.4 39 79.6 <0.0001
dead 17 3.6 10 20.4
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shorter RFS and OS. Lymph node metastasis is generally
the most important prognostic factor in breast cancer
patients [12]. In this study, VEGFR-1 mRNA expression
was shown to be associated with lymph node metastasis
and to influence prognosis. In addition, multivariate
analysis revealed that VEGFR-1 mRNA expression in
peripheral blood was an independent prognostic factor,
in addition to lymph node metastasis and hormone
receptor status. We speculate that VEGFR-1 expression
in the peripheral blood at the time of surgery has a
higher sensitivity as a prognostic factor in breast cancer
patients.
We hypothesized that the original cells expressing
VEGFR-1 in breast cancer patients are monocytes, circu-
lating endothelial cells, circulating cancer cells and hema-
topoietic progenitor cells (HPCs). Our previous study
revealed that the original cells producing VEGFR-1 may
be monocytes [10]. Jain et al. revealed that the frequency
Figure 3 Kaplan-Meier relapse free survival (A) and overall survival (B) curves. Patients in the high expression group of VEGFR-1 mRNA
showed significantly high recurrence (P <0.05) and poorer prognosis (P <0.01) than those in the low-expression group (log rank test).
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of peripheral blood VEGFR1+ HPCs in patients with
breast cancer was increased prior to relapse and could be
used to predict disease progression in metastatic breast
cancer patients [13]. Therefore, we have been interested
in changes of VEGFR-1 mRNA in the blood of breast
cancer patients before recurrence.
Recently, DNA microarray profiling has identified dis-
tinct subtypes of breast cancer. Sorlie et al. categorized
expression profiles into five molecular subtypes: luminal
A, luminal B, HER2, normal breast-like and basal-like
[14]. These breast cancer subtypes are associated with
different clinical outcomes, from the relatively good
prognosis of patients with luminal A tumors to the worst
prognosis of those with basal-like and HER2-positive
tumors [15]. Ki-67 expression is chiefly important in dis-
tinguishing between ‘Luminal A’ and ‘Luminal B (HER2
negative)’ subtypes. Chemotherapy is indicated for most
patients with ‘Luminal B’ disease [16]. Based upon the
results of this study (Figure 4a), VEGFR-1 mRNA expres-
sion in peripheral blood may be useful for choice of adju-
vant chemotherapy in Luminal type (HER2 negative)
breast cancer. However, further studies are needed to
analyze both Ki67 and VEGFR-1 expression. Basal-like
breast cancer does not express estrogen receptor, proges-
terone receptor and HER2 (so called triple-negative
breast cancer). Therefore, the only treatment available
for basal-like cancer patients is systemic chemotherapy.
Basal-like cancer is associated with an aggressive clinical
course, distant metastasis (for example, to the brain,
liver, lung and bone), and poor prognosis [17,18]. The
results of the present study indicate that patients with
VEGFR-1 -positive triple-negative cancer had a particu-
larly poor prognosis (Figure 4b). Therefore, VEGFR-1
mRNA may be a useful marker for identifying poor prog-
nosis in patients with triple-negative cancer. For such
cases, an additional course of chemotherapy or close fol-
low-up may be recommended.
VEGFR-1 expression was not significantly different in
patients who were positive for HER2. The reason may be
we had unknown HER2 data with some cases. Further-
more, the group positive for VEGFR-1 was small, and the
chemotherapeutic regimen (including use of trastuzumab,
the anti-HER2 antibody) was different from that used
today.
Recently, molecularly targeted therapies (for example, the
anti-HER2 antibody trastuzumab) have played an increas-
ingly critical role in breast cancer treatment. Sunitinib and
sorafenib are tyrosine kinase inhibitors (TKIs) with novel
molecular targets, including VEGFR-1. Sunitinib is a small-
molecule multi-TKI that targets multiple vascular endothe-
lial growth factor receptors (VEGFRs), platelet-derived
growth factor receptor (PDGFR), KIT and colony-stimulat-
ing factor 1 receptor [19]. In a breast cancer clinical trial,
sunitinib demonstrated a benefit in 38.9% of 18 patients
with previously treated metastatic breast cancer [20]. In a
Phase II study, sunitinib treatment resulted in a partial
response in 7 of 64 patients with heavily pretreated meta-
static breast cancer [21]. However, a Phase III study of
sunitinib combination with docetaxel improved response
rate but did not prolong survival [22]. Sorafenib is a multi-
kinase inhibitor that targets several receptor tyrosine
kinases including, VEGFR-1, -2 and -3 and PDGFR-b, and
serine threonine kinases including, Raf-1 and B-Raf, all
shown to be involved in neovascularization and tumor pro-
gression [23,24]. In a Phase II randomized trial in breast
cancer patients, the addition of sorafenib to capecitabine
therapy significantly improved progression-free survival
compared with capecitabine alone [25]. A large Phase III
trial is currently evaluating this combination in a large
number of breast cancer patients. We expect that VEGFR-
1 might be useful as a biomarker, considering the efficacy
of the TKIs described above.
Conclusions
The evaluation of VEGFR-1 mRNA in the peripheral
blood of breast cancer patients may play a very impor-
tant role in the prediction of cancer metastasis and
recurrence.
Table 3 Univariate and multivariate analysis for overall survival
Univariate analysis Multivariate analysis
Factors RR 95% CI P RR 95% CI P
Lymphnode metastasis (negative/positive) 2.91 1.86 to 5.03 <0.0001 2.67 1.53 to 4.96 <0.001
Hormone receptor (positive/negative) 2.37 1.61 to 3.59 <0.0001 2.65 1.62 to 4.43 0.0001
VEGFR-1 mRNA expression (negative/positive) 1.86 1.19 to 2.79 <0.01 2.00 1.19 to 3.25 <0.01
CEA (<5.0 ng/ml/ >5.1 ng/ml) 2.23 1.20 to 3.65 <0.05 1.69 0.87 to 2.95 0.11
Tumor size (small/large) 2.14 1.26 to 4.39 <0.01 1.63 0.85 to 4.13 0.16
Nuclear grade (I and II/III) 1.62 1.11 to 2.39 <0.05 1.25 0.82 to 1.89 0.29
Lymphatic involvement (negative/positive) 1.51 1.03 to 2.26 <0.05 0.99 0.62 to 1.61 0.96
Vascular involvement (negative/positive) 1.85 1.00 to 3.01 0.05 - - -
HER-2/NEU (negative/positive) 1.48 0.96 to 2.26 0.08 - - -
CI, Confidence interval; RR, Relative risk
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